Literature DB >> 19917203

Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea.

Jacqueline A Upcroft1, Linda A Dunn, Tilda Wal, Sepehr Tabrizi, Maria G Delgadillo-Correa, Patricia J Johnson, Suzanne Garland, Peter Siba, Peter Upcroft.   

Abstract

BACKGROUND: The prevalence of the sexually transmissible protozoan parasite Trichomonas vaginalis in the highlands of Papua New Guinea (PNG) has been reported to be as high as 46% and although not previously studied in Papua New Guinea, clinical resistance against metronidazole (Mz), the drug most commonly used to treat trichomoniasis, is well documented worldwide. This study was primarily aimed at assessing resistance to Mz in T. vaginalis strains from the Goroka region.
METHODS: Consenting patients presenting at the Goroka Base Hospital Sexually Transmitted Diseases (STD) Clinic and local women were asked to provide two vaginal swabs: one for culturing of the parasite; and one for polymerase chain reaction detection of T. vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae. T. vaginalis isolates were assayed for Mz susceptibility and a selection was genotyped.
RESULTS: The prevalence of T. vaginalis was determined to be 32.9% by culture and polymerase chain reaction of swabs among 82 local women and patients from the STD clinic. An unexpectedly high level of in vitro Mz resistance was determined with 17.4% of isolates displaying unexpectedly high resistance to Mz. The ability to identify isolates of T. vaginalis by genotyping was confirmed and the results revealed a more homogeneous T. vaginalis population in Papua New Guinea compared with isolates from elsewhere.
CONCLUSION: T. vaginalis is highly prevalent in the Goroka region and in vitro Mz resistance data suggest that clinical resistance may become an issue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917203     DOI: 10.1071/SH09011

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  19 in total

1.  Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.

Authors:  Janelle M Wright; Linda A Dunn; Zygmunt Kazimierczuk; Anita G Burgess; Kenia G Krauer; Peter Upcroft; Jacqueline A Upcroft
Journal:  Parasitol Res       Date:  2010-06-09       Impact factor: 2.289

2.  20S Proteasome as a Drug Target in Trichomonas vaginalis.

Authors:  Anthony J O'Donoghue; Betsaida Bibo-Verdugo; Yukiko Miyamoto; Steven C Wang; Justin Z Yang; Douglas E Zuill; Shoun Matsuka; Zhenze Jiang; Jehad Almaliti; Conor R Caffrey; William H Gerwick; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.

Authors:  Melissa Hopper; Jeong-Fil Yun; Bianhua Zhou; Christine Le; Katelin Kehoe; Ryan Le; Ryan Hill; Gregg Jongeward; Anjan Debnath; Liangfang Zhang; Yukiko Miyamoto; Lars Eckmann; Kirkwood M Land; Lisa A Wrischnik
Journal:  Int J Antimicrob Agents       Date:  2016-11-02       Impact factor: 5.283

Review 4.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

Review 5.  Getting trichy: tools and approaches to interrogating Trichomonas vaginalis in a post-genome world.

Authors:  Melissa D Conrad; Martina Bradic; Sally D Warring; Andrew W Gorman; Jane M Carlton
Journal:  Trends Parasitol       Date:  2012-12-05

6.  Trichomonas vaginalis flavin reductase 1 and its role in metronidazole resistance.

Authors:  David Leitsch; Brian D Janssen; Daniel Kolarich; Patricia J Johnson; Michael Duchêne
Journal:  Mol Microbiol       Date:  2013-11-20       Impact factor: 3.501

7.  Down-regulation of flavin reductase and alcohol dehydrogenase-1 (ADH1) in metronidazole-resistant isolates of Trichomonas vaginalis.

Authors:  David Leitsch; Mirjana Drinić; Daniel Kolarich; Michael Duchêne
Journal:  Mol Biochem Parasitol       Date:  2012-03-17       Impact factor: 1.759

8.  Study on ITS1 Gene of Iranian Trichomonas vaginalis by Molecular Methods.

Authors:  F Kazemi; H Hooshyar; B Zareikar; M Bandehpour; M Arbabi; S Talari; R Alizadeh; B Kazemi
Journal:  Iran J Parasitol       Date:  2010-12       Impact factor: 1.012

9.  Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010.

Authors:  Robert D Kirkcaldy; Peter Augostini; Lenore E Asbel; Kyle T Bernstein; Roxanne P Kerani; Christie J Mettenbrink; Preeti Pathela; Jane R Schwebke; W Evan Secor; Kimberly A Workowski; Darlene Davis; Jim Braxton; Hillard S Weinstock
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

10.  Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in Trichomonas vaginalis.

Authors:  Yukiko Miyamoto; Shubhangi Aggarwal; Jeff Joseph A Celaje; Sozaburo Ihara; Jonathan Ang; Dmitry B Eremin; Kirkwood M Land; Lisa A Wrischnik; Liangfang Zhang; Valery V Fokin; Lars Eckmann
Journal:  J Med Chem       Date:  2021-05-11       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.